312-58-3Relevant academic research and scientific papers
BENZENE SULFONAMIDE DERIVATIVES AND THEIR USE AS RORC MODULATORS
-
Page/Page column 56, (2015/12/08)
Compounds of the formula la or lb: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, D, E, G, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS
-
Paragraph 0442, (2014/06/24)
Compounds of the formula Ia or Ib: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
Novel lithium and sodium salts of sulfonamides and bis(sulfonyl)imides: Synthesis and electrical conductivity
Morizur, Vincent,Olivero, Sandra,Desmurs, Jean Roger,Knauth, Philippe,Duach, Elisabet
, p. 6193 - 6197 (2015/02/19)
The preparation of new electrolytes for application in lithium or sodium batteries is described. Different salts of lithium and sodium sulfonamide and bis(sulfonyl)imide were prepared in good yields. Ionic conductivity measurements were performed on these salts and conductivities of 0.20 to 0.51 mS cm-1, comparable to those of Li-TFSI, were obtained. The best conductivity was reached for the Li+ salt of a bis(sulfonyl)imide bearing CF3 and 4-FC6H4 groups. This journal is
SUBSTITUTED SULFONAMIDE COMPOUNDS
-
Page/Page column 117, (2014/04/17)
The invention is concerned with the compounds of formula (I), and salts thereof, wherein X, Y, Z, R1, R2, R3, R3, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
